Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play

Emerging Microbes and Infections

Volumn 5, Issue 1, 2016, Pages 1-9

  Lambour, Jennifer ^a,b   Naranjo Gomez, Mar ^a,b   Piechaczyk, Marc ^a,b   Pelegrin, Mireia ^a,b  

^a CNRS   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

antiviral therapy; DC; Fc receptors; immune complexes; immunotherapy; monoclonal antibodies; vaccine strategies; vaccine like effects

Indexed keywords

ANTIGEN ANTIBODY COMPLEX; ANTIVIRUS AGENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ACTIVE IMMUNOTHERAPY; ANIMAL; ANTIGEN ANTIBODY COMPLEX; DISEASE MODEL; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; PASSIVE IMMUNIZATION; VACCINATION; VIRUS DISEASES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY, ACTIVE; VACCINATION; VIRUS DISEASES;

EID: 85011564563     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2016.97     Document Type: Review

References (101)

1. Irani V,Guy AJ,Andrew D,Beeson JG,Ramsland PA,Richards JS.Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.Mol Immunol2015; 67:171–182.
2. Vacchelli E,Eggermont A, et alGalon J.Oncoimmunology2013; 2:e22789.
3. Bornholdt ZA,Turner HL, et alMurin CD.Science2016; 351:1078–1083.
4. Corti D,Misasi J, et alMulangu S.Science2016; 351:1339–1342.
5. Corti D,Zhao J, et alPedotti M.Proc Natl Acad Sci USA2015; 112:10473–10478.
6. Johnson RF,Bagci U, et alKeith L.Virology2016; 490:49–58.
7. Qiu X,Wong G, et alAudet J.Nature2014; 514:47–53.
8. Barouch DH,Whitney JB, et alMoldt B.Nature2013; 503:224–228.
9. Berry JD,Gaudet RG.Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology.N Biotechnol2011; 28:489–501.
10. Both L,Banyard AC,van Dolleweerd C,Wright E,Ma JK,Fooks AR.Monoclonal antibodies for prophylactic and therapeutic use against viral infections.Vaccine2013; 31:1553–1559.
11. Corti D,Lanzavecchia A.Broadly neutralizing antiviral antibodies.Annu Rev Immunol2013; 31:705–742.
12. de Jong YP,Dorner M, et alMommersteeg MC.Sci Transl Med2014; 6:254ra129.
13. Dejnirattisai W,Wongwiwat W, et alSupasa S.Nat Immunol2015; 16:170–177.
14. Flego M,Ascione A,Cianfriglia M,Vella S.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.BMC Med2013; 11:4.
15. Flyak AI,Ilinykh PA, et alMurin CD.Cell2015; 160:893–903.
16. Flyak AI,Shen X, et alMurin CD.Cell2015; 164:392–405.
17. Gautam R,Nishimura Y, et alPegu A.Nature2016; 533:105–109.
18. Hessell AJ,Jaworski JP, et alEpson E.Nat Med2016; 22:362–368.
19. Krawczyk A,Arndt MA, et alGrosse-Hovest L.Proc Natl Acad Sci USA2013; 110:6760–6765.
20. Marasco WA,Sui J.The growth and potential of human antiviral monoclonal antibody therapeutics.Nat Biotechnol2007; 25:1421–1434.
21. Tan Y,Ng Q,Jia Q,Kwang J,He F.A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.J Virol2015; 89:3712–3722.
22. Williams KL,Sukupolvi-Petty S, et alBeltramello M.PLoS Pathog2013; 9:e1003157.
23. Caskey M,Klein F, et alLorenzi JC.Nature2015; 522:487–491.
24. Lynch RM,Boritz E, et alCoates EE.Sci Transl Med2015; 7:319ra206.
25. Bruhns P,Jonsson F.Mouse and human FcR effector functions.Immunol Rev2015; 268:25–51.
26. Pincetic A,Bournazos S, et alDiLillo DJ.Nat Immunol2014; 15:707–716.
27. Euler Z,Alter G.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.AIDS Res Hum Retroviruses2014; 31:13–24.
28. Hessell AJ,Haigwood NL.Neutralizing antibodies and control of HIV: moves and countermoves.Curr HIV/AIDS Rep2012; 9:64–72.
29. Su B,Moog C.Which antibody functions are important for an HIV vaccine?Front Immunol2014; 5:289.
30. Nimmerjahn F,Gordan S,Lux A.FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.Trends Immunol2015; 36:325–336.
31. Malbec M,Porrot F, et alRua R.J Exp Med2013; 210:2813–2821.
32. Bruhns P.Properties of mouse and human IgG receptors and their contribution to disease models.Blood2012; 119:5640–5649.
33. Getahun A,Heyman B.How antibodies act as natural adjuvants.Immunol Lett2006; 104:38–45.
34. Heyman B.Antibodies as natural adjuvants.Curr Top Microbiol Immunol2014; 382:201–219.
35. Hjelm F,Carlsson F,Getahun A,Heyman B.Antibody-mediated regulation of the immune response.Scand J Immunol2006; 64:177–184.
36. Nimmerjahn F,Ravetch JV.Fcgamma receptors as regulators of immune responses.Nat Rev Immunol2008; 8:34–47.
37. Schwab I,Nimmerjahn F.Intravenous immunoglobulin therapy: how does IgG modulate the immune system?Nat Rev Immunol2013; 13:176–189.
38. Brady LJ.Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.Infect Immun2005; 73:671–678.
39. Pelegrin M,Naranjo-Gomez M,Piechaczyk M.Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?Trends Microbiol2015; 23:653–665.
40. Gros L,Dreja H,Fiser AL,Plays M,Pelegrin M,Piechaczyk M.Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.J Virol2005; 79:6272–6280.
41. Gros L,Pelegrin M, et alMichaud HA.J Virol2008; 82:1339–1349.
42. Gros L,Pelegrin M,Plays M,Piechaczyk M.Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy.J Virol2006; 80:10191–10200.
43. Michaud HA,Gomard T, et alGros L.PLoS Pathog2010; 6:e1000948.
44. Nasser R,Pelegrin M, et alMichaud HA.J Virol2010; 84:10169–10181.
45. Nasser R,Pelegrin M,Plays M,Gros L,Piechaczyk M.Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies.Blood2013; 121:1102–1111.
46. Boyoglu-Barnum S,Chirkova T, et alTodd SO.J Virol2014; 88:10569–10583.
47. Bossart KN,Geisbert TW, et alFeldmann H.Sci Transl Med2011; 3:105ra103.
48. Geisbert TW,Mire CE, et alGeisbert JB.Sci Transl Med2014; 6:242ra282.
49. Jaworski JP,Kobie J, et alBrower Z.J Virol2013; 87:10447–10459.
50. Ng CT,Jaworski JP, et alJayaraman P.Nat Med2010; 16:1117–1119.
51. Watkins JD,Siddappa NB, et alLakhashe SK.PLoS One2011; 6:e18207.
52. Schoofs T,Klein F, et alBraunschweig M.Science2016; 352:997–1001.
53. Bournazos S,Klein F,Pietzsch J,Seaman MS,Nussenzweig MC,Ravetch JV.Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.Cell2014; 158:1243–1253.
54. Halper-Stromberg A,Lu CL, et alKlein F.Cell2014; 158:989–999.
55. Celis E,Chang TW.HBsAg-serum protein complexes stimulate immune T lymphocytes more efficiently than do pure HBsAg.Hepatology1984; 4:1116–1123.
56. Zheng BJ,Zhou J, et alQu D.J Viral Hepat2004; 11:217–224.
57. Villinger F,Mayne AE, et alBostik P.J Virol2003; 77:10–24.
58. Yamamoto T,Iwamoto N, et alYamamoto H.J Virol2009; 83:5514–5524.
59. Posch W,Cardinaud S, et alHamimi C.J Allergy Clin Immunol2012; 130:1368–1374 e1362.
60. Xu DZ,Huang KL, et alZhao K.Vaccine2005; 23:2658–2664.
61. Yao X,Zheng B, et alZhou J.Vaccine2007; 25:1771–1779.
62. Xu DZ,Zhao K, et alGuo LM.PLoS One2008; 3:e2565.
63. Liu H,Geng S, et alWang B.Hum Vaccin Immunother2015; 12:77–84.
64. Leon B,Ballesteros-Tato A,Randall TD,Lund FE.Prolonged antigen presentation by immune complex-binding dendritic cells programs the proliferative capacity of memory CD8 T cells.J Exp Med2014; 211:1637–1655.
65. Kruijsen D,Bakkers MJ, et alvan Uden NO.J Immunol2010; 185:6489–6498.
66. Duhan V,Khairnar V, et alFriedrich SK.Sci Rep2016; 6:19191.
67. Bachmann MF,Hunziker L,Zinkernagel RM,Storni T,Kopf M.Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key.Eur J Immunol2004; 34:317–326.
68. Bergthaler A,Flatz L, et alVerschoor A.PLoS Biol2009; 7:e80.
69. Terres G,Wolins W.Enhanced immunological sensitization of mice by the simultaneous injection of antigen and specific antiserum. I. Effect of varying the amount of antigen used relative to the antiserum.J Immunol1961; 86:361–368.
70. Wen YM,Qu D,Zhou SH.Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.Int Rev Immunol1999; 18:251–258.
71. Basalp A,Cirakoglu B,Bermek E.Enhancement of the immune response to hepatitis B virus vaccine by antigen specific IgM.Immunol Lett2000; 73:1–6.
72. Zheng BJ,Ng MH, et alHe LF.Vaccine2001; 19:4219–4225.
73. Lu M,Yao X, et alXu Y.J Virol2008; 82:2598–2603.
74. McCluskie MJ,Wen YM,Di Q,Davis HL.Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes.Viral Immunol1998; 11:245–252.
75. Hioe CE,Visciano ML, et alKumar R.Vaccine2009; 28:352–360.
76. Kumar R,Tuen M,Li H,Tse DB,Hioe CE.Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.Vaccine2011; 29:9064–9074.
77. Kumar R,Tuen M, et alLiu J.Vaccine2013; 31:5413–5421.
78. Kruijsen D,Einarsdottir HK, et alSchijf MA.J Virol2013; 87:7550–7557.
79. Randall RE,Young DF,Southern JA.Immunization with solid matrix-antibody-antigen complexes containing surface or internal virus structural proteins protects mice from infection with the paramyxovirus, simian virus 5.J Gen Virol1988; 69:2517–2526.
80. Randall RE,Young DF.Solid matrix-antibody-antigen complexes induce antigen-specific CD8+ cells that clear a persistent paramyxovirus infection.J Virol1991; 65:719–726.
81. Xu DZ,Wang XY, et alShen XL.J Hepatol2013; 59:450–456.
82. Berzofsky JA,Bensussan A, et alCease KB.Nature1988; 334:706–708.
83. Kumar R,Visciano ML,Li H,Hioe C.Targeting a neutralizing epitope of HIV envelope Gp120 by immune complex vaccine.J AIDS Clin Res2012; S8:pii: 5512.
84. Tsouchnikas G,Zlatkovic J, et alJarmer J.J Virol2015; 89:7970–7978.
85. Rival C,Samy E,Setiady Y,Tung K.Cutting edge: Ly49C/I(-) neonatal NK cells predispose newborns to autoimmune ovarian disease induced by maternal autoantibody.J Immunol2013; 191:2865–2869.
86. Rival C,Setiady Y,Samy ET,Harakal J,Tung KS.The unique neonatal NK cells: a critical component required for neonatal autoimmune disease induction by maternal autoantibody.Front Immunol2014; 5:242.
87. Wieland A,Shashidharamurthy R, et alKamphorst AO.Immunity2015; 42:367–378.
88. Yamada DH,Elsaesser H, et alLux A.Immunity2015; 42:379–390.
89. Moir S,Fauci AS.B cells in HIV infection and disease.Nat Rev Immunol2009; 9:235–245.
90. Liu P,Overman RG, et alYates NL.J Virol2011; 85:11196–11207.
91. Riva E,Maggi F, et alAbbruzzese F.Med Microbiol Immunol2009; 198:13–18.
92. Acosta EG,Bartenschlager R.Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.Expert Rev Vaccines2016; 15:467–482.
93. Halstead SB.Dengue antibody-dependent enhancement: knowns and unknowns.Microbiol Spectr2014 doi:10.1128/microbiolspec.AID-0022-2014.
94. Halstead SB,Mahalingam S,Marovich MA,Ubol S,Mosser DM.Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.Lancet Infect Dis2010; 10:712–722.
95. Ubol S,Halstead SB.How innate immune mechanisms contribute to antibody-enhanced viral infections.Clin Vaccine Immunol2010; 17:1829–1835.
96. Tsai TT,Chuang YJ, et alLin YS.PLoS Negl Trop Dis2014; 8:e3320.
97. Perreau M,Pantaleo G,Kremer EJ.Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.J Exp Med2008; 205:2717–2725.
98. Bengsch B,Martin B,Thimme R.Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.J Hepatol2014; 61:1212–1219.
99. Gardiner D,Lalezari J, et alLawitz E.PLoS One2013; 8:e63818.
100. Sharma P,Allison JP.Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.Cell2015; 161:205–214.
101. Sherman AC,Trehanpati N, et alDaucher M.AIDS Res Hum Retroviruses2013; 29:665–672.